A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Japan Clinical Oncology Group.
Recruitment status was  Active, not recruiting
Ministry of Health, Labour and Welfare, Japan
Information provided by:
Japan Clinical Oncology Group
ClinicalTrials.gov Identifier:
First received: September 1, 2005
Last updated: February 2, 2009
Last verified: February 2009
To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic irradiation.

Condition Intervention Phase
Small-Cell-Lung Cancer
Drug: Etoposide and cisplatin after chemoradiotherapy
Drug: Irinotecan and cisplatin after chemoradiotherapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF

Resource links provided by NLM:

Further study details as provided by Japan Clinical Oncology Group:

Primary Outcome Measures:
  • overall survival [ Time Frame: during the study conduct ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • adverse events of induction chemoradiotherapy [ Time Frame: during the study conduct ] [ Designated as safety issue: Yes ]
  • chemotherapy after chemoradiotherapy [ Time Frame: during the study conduct ] [ Designated as safety issue: No ]
  • late radiation morbidity [ Time Frame: during the study conduct ] [ Designated as safety issue: Yes ]
  • serious adverse event [ Time Frame: during the study conduct ] [ Designated as safety issue: Yes ]
  • progression-free survival [ Time Frame: during the study conduct ] [ Designated as safety issue: No ]

Enrollment: 281
Study Start Date: September 2002
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Etoposide and cisplatin after chemoradiotherapy
Drug: Etoposide and cisplatin after chemoradiotherapy
Etoposide and cisplatin after chemoradiotherapy
Experimental: 2
Irinotecan and cisplatin after chemoradiotherapy
Drug: Irinotecan and cisplatin after chemoradiotherapy
Irinotecan and cisplatin after chemoradiotherapy

Detailed Description:
The Japan Clinical Oncology Group (JCOG) previously conducted a randomized phase III trial comparing irinotecan and cisplatin (IP) with EP in patients with extensive-stage SCLC. The response rate and overall median survival were significantly better for IP, i.e. 84.4% and 12.8 months with IP, versus 67.5% and 9.4 months with EP, respectively. The 2-year survival rates were 19.5% for IP and 5.2% for EP (7). These encouraging results prompted us to explore the use of IP in LSCLC.

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. cytologically, histologically proven small-cell lung cancer
  2. limited disease
  3. age 20-70 years old
  4. performance status of 0-1
  5. measurable disease
  6. no prior treatment for small-cell lung cancer
  7. no history of chemotherapy
  8. adequate organ functions
  9. written informed consent

Exclusion Criteria:

  1. pericardial effusion
  2. active concomitant malignancy
  3. pregnant or lactating women
  4. interstitial pneumonia/active lung fibrosis on chest x-ray, watery diarrhea, intestinal obstruction or paralysis, uncontrolled heart disease or a history of myocardial infarction within the previous 6 months, uncontrolled diabetes mellitus, active infection, psychological disease deemed unacceptable for inclusion to the study, long-term steroid treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00144989

Aichi Cancer Center Hospital
1-1,Kanokoden,Chikusa-ku,Nagoya, Aichi, Japan, 464-8681
Aichi Cancer Center,Aichi Hospital
18,Kuriyado,Kake-machi,Okazaki, Aichi, Japan, 444-0011
National Cancer Center Hospital East
6-5-1 kashiwanoha Kashiwa-shi, Chiba, Japan, 277-8577
National Hospital Organization Shikoku Cancer Center
13,Horinouchi,Matsuyama, Ehime, Japan, 790-0007
Kyushu University Hospital
3-1-1,Maidashi,Higashi-ku, Fukuoka, Japan, 812-8582
Gifu Municipal Hospital
7-1,Kashima-cho,Gifu, Gifu, Japan, 500-8323
National Nishigunma Hospital
2854, Kanai,Shibukawa, Gunma, Japan, 377-8511
Gunma Prefectural Cancer Center
617-1,Takabayashi-nishi-cho,Ota, Gunma, Japan, 373-8550
National Hospital Organization Hokkaido Cancer Center
4-2-3-54,Kikusui,Shiroishi-ku,Sapporo, Hokkaido, Japan, 003-0804
National Hospital Organization, Dohoku National Hospital
7-4048,Hanasaki,Asahikawa, Hokkaido, Japan, 070-8644
Hyogo College of Medicine
1-1,Mukogawa-cho,Nishinomiya, Hyogo, Japan, 663-8501
Hyogo Medical Center for Adults
13-70,Kitaouji-cho,Akashi, Hyogo, Japan, 673-8558
Kobe City General Hospital
4-6,Minatojimanakamachi,Chuo-ku,Kobe, Hyogo, Japan, 650-0046
Ibaraki Kenritsu Chuo Hospital & Cancer Center
6528 Koibuchi,Tomobemachi,Nishi-ibarakigun, Ibaraki, Japan, 309-1793
Kanagawa Cancer Center
1-1-2,Nakao,Asahi-ku,Yokohama, Kanagawa, Japan, 241-0815
Yokohama Mucipical Citizen's Hospital
56,Okazawa-cho,Hodogaya-ku,Yokohama, Kanagawa, Japan, 240-8555
Kumamoto Regional Medical Center Hospital
5-16-10,Honjo,Kumamoto, Kumamoto, Japan, 860-0811
Tohoku University Hospital
1-1,Seiryo-machi,Aoba-ku,Sendai, Miyagi, Japan, 980-0874
Niigata Cancer Center Hospital
2-15-3,Kawagishi-cho,Niigata, Niigata, Japan, 951-8566
Okayama University Hospital
2-5-1,Shikata-cho,Okayama, Okayama, Japan, 700-8558
Osaka Medical Center for Cancer and Cardiovascular Diseases
1-3-3,Nakamichi,Higashinari-ku,Osaka, Osaka, Japan, 537-8511
Graduate School of Medicine, Osaka City University
1-5-7,Asahi-machi,Abeno-ku,Osaka, Osaka, Japan, 545-0051
National Hospital Organization Kinki-Chuo Chest Medical Center
1180,Nagasone,Sakai, Osaka, Japan, 591-8555
Osaka City General Hospital
2-13-22,Miyakojimahondori,Miyakojima-ku,Osaka, Osaka, Japan, 534-0021
Rinku General Medical Center
2-23,rinku-ohrai-kita,Izumisano, Osaka, Japan, 598-0048
Osaka General Medical Center
3-1-56,Bandai-higashi,Sumiyoshi-ku,Osaka, Osaka, Japan, 558-8558
Osaka Prefectural Medical Center for Respiratory and Allergic Disease
3-7-1,Habikino,Habikino, Osaka, Japan, 583-8588
Kinki University School of Medicine
377-2,Ohno-higashi,Osaka-Sayama, Osaka, Japan, 589-8511
National Hospital Organization Toneyama National Hospital
5-1-1,Toneyama,Toyonaka, Osaka, Japan, 560-8552
Saitama Cancer Center
818,Komuro,Ina,Kita-adachi, Saitama, Japan, 362-0806
Sizuoka Cancer Center
1007,Shimonagakubo,Nagaizumi-cho,Sunto-gun, Shizuoka, Japan, 411-8777
Tochigi Cancer Center
4-9-13,Yohnan,Utsunomiya, Tochigi, Japan, 320-0834
International Medical Center of Japan
1-21-1,Toyama,Shinjuku-ku, Tokyo, Japan, 162-8655
Toranomon Hospital
2-2-2,Toranomon,Minato-ku, Tokyo, Japan, 105-8470
Cancer Institute Hospital
3-10-6,Ariake,Koto-ku, Tokyo, Japan, 135-8550
National Cancer Center Hospital
5-1-1,Tsukiji,Chuo-ku, Tokyo, Japan, 104-0045
Yamagata Prefectural Central Hospital
1800,Aoyagi,Yamagata, Yamagata, Japan, 990-2292
Sponsors and Collaborators
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan
Study Chair: Yutaka Nishiwaki, MD National Cancer Center Hospital East
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Japan Clinical Oncology Group
ClinicalTrials.gov Identifier: NCT00144989     History of Changes
Other Study ID Numbers: JCOG0202-MF  C000000095 
Study First Received: September 1, 2005
Last Updated: February 2, 2009
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Japan Clinical Oncology Group:
Small-cell lung cancer
Limited-Stage Small-Cell Lung Cancer
Combined modality therapy

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Etoposide phosphate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase II Inhibitors

ClinicalTrials.gov processed this record on August 25, 2016